SynthesisExperimental gerontology2016
Telomere length in Parkinson's disease: A meta-analysis.
Synthesis in Experimental gerontology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 68 citations in OpenAlex.
- Article
- Investigating the ageing-Parkinson's disease nexus: standardisation of in vitro models and techniques by the PD-AGE network.NPJ Parkinson's disease · 2025Review
- The Hallmarks of Ageing in Microglia.Cellular and molecular neurobiology · 2025Review
- The relationship between telomere length and aging-related diseases.Clinical and experimental medicine · 2025Review
- Aging, cellular senescence and Parkinson's disease.Journal of Parkinson's disease · 2025Review
- Nutrition, Immunity and Aging: Current Scenario and Future Perspectives in Neurodegenerative Diseases.CNS & neurological disorders drug targets · 2024Review
- Article
- Age-related telomere attrition in the human putamen.Aging cell · 2023Article
- Targeting the Cysteine Redox Proteome in Parkinson's Disease: The Role of Glutathione Precursors and Beyond.Antioxidants (Basel, Switzerland) · 2023Review
- Leukocyte Telomere Length as Potential Biomarker of HD Progression: A Follow-Up Study.International journal of molecular sciences · 2022Article
- Leukocyte Telomere Length Variability as a Potential Biomarker in Patients with PolyQ Diseases.Antioxidants (Basel, Switzerland) · 2022Article
- Is Telomere Length Shortening a Risk Factor for Neurodegenerative Disorders?Dementia and neurocognitive disorders · 2022Review
- Retinal age gap as a predictive biomarker of future risk of Parkinson's disease.Age and ageing · 2022Article
- Telomere dysfunction in ageing and age-related diseases.Nature cell biology · 2022Review
- Fisetin as a Senotherapeutic Agent: Biopharmaceutical Properties and Crosstalk between Cell Senescence and Neuroprotection.Molecules (Basel, Switzerland) · 2022Review
- Age-Related Adaptive Immune Changes in Parkinson's Disease.Journal of Parkinson's disease · 2022Review
- Integrated Multi-Omics for Novel Aging Biomarkers and Antiaging Targets.Biomolecules · 2021Review
- T lymphocyte senescence is attenuated in Parkinson's disease.Journal of neuroinflammation · 2021Article
- Assessment of the Telomere Length and Its Effect on the Symptomatology of Parkinson's Disease.Antioxidants (Basel, Switzerland) · 2021Article
- Leukocyte Telomere Length Is Unrelated to Cognitive Performance Among Non-Demented and Demented Persons: An Examination of Long Life Family Study Participants.Journal of the International Neuropsychological Society : JINS · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 4 countries.
Funding
Abstract
Parkinson's disease (PD) is a common and severe movement disorder. Differences in telomere length (TL) have been reported as possible risk factors for several neuropsychiatric disorders, including PD. Results from published studies for TL in PD are inconsistent, highlighting the need for a meta-analysis. In the current work, a meta-analysis of published studies for TL in PD was carried out. PubMed, Web of Science and Google Scholar databases were used to identify relevant articles that reported TL in groups of PD patients and controls. A random-effects model was used for meta-analytical procedures. The meta-analysis included eight primary studies, derived from populations of European and Asian descent, and did not show a significant difference in TL between 956 PD patients and 1284 controls (p value: 0.246). Our results show that there is no consistent evidence of shorter telomeres in PD patients and suggest the importance of future studies on TL and PD that analyze other populations and also include assessment of TL from different brain regions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.